Screener / SEC EDGAR /CIK 0001159036 /10-K filed Feb 17, 2026, compared with Feb 18, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Halozyme Therapeutics, Inc. HALO

Compare with peers Embed
Planned sales, announced before they happen

3 trading plans running, 12 Form 144 notices for $53.4M

10-Q, 10-K and Form 144

What HALO's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.

Plans adopted or ended

Trading plans · XBRL, 10-Q and 10-K

From Mar 22, 2024 to Jul 30, 2027. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired.

InsiderWhatDateReported in
Matthew Posard
Director
Adopted 10b5-1 plan Jun 15, 2026 10-Q Aug 6, 2026
Mahesh Krishnan
Director
Adopted 10b5-1 plan Mar 19, 2026 10-Q May 11, 2026
Helen Torley
President and Chief Executive Officer
Adopted 10b5-1 plan Dec 3, 2025 10-K Feb 17, 2026
Nicole LaBrosse
Senior Vice President and Chief Financial Officer
Ended 10b5-1 plan Dec 2, 2025 10-K Feb 17, 2026
Nicole LaBrosse
Senior Vice President and Chief Financial Officer
Adopted 10b5-1 plan Jun 11, 2025 10-Q Aug 5, 2025
Bernadette Connaughton
Director
Adopted 10b5-1 plan May 29, 2025 10-Q Aug 5, 2025
Helen Torley
President and Chief Executive Officer
Adopted 10b5-1 plan Mar 21, 2025 10-Q May 6, 2025
Michael J. LaBarre
Senior Vice President and Chief Technical Officer
Adopted 10b5-1 plan Sep 18, 2024 10-Q Oct 31, 2024
Jeffrey W. Henderson
Director (Board Chair)
Adopted 10b5-1 plan Sep 17, 2024 10-Q Oct 31, 2024
Nicole LaBrosse
Senior Vice President and Chief Financial Officer
Adopted 10b5-1 plan Mar 22, 2024 10-Q May 7, 2024
Helen Torley
President and Chief Executive Officer
Ended 10b5-1 plan Jan 30, 2024 10-Q May 7, 2024
Show the other 3 plans

From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 9, 2023.

Notices of planned sales

Form 144 · Form 144 XML, SEC

What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).

FiledSellerSharesValue
Sep 16, 2026 MATTHEW POSARD
Director
34,226 $3.6M
Aug 17, 2026 Helen Torley
President, CEO, Director
240,000 $23.7M
Aug 11, 2026 CORTNEY A CAUDILL
Officer
41,702 $4.3M
Aug 10, 2026 BERNADETTE CONNAUGHTON
Director
1,626 $168K
Jun 29, 2026 MAHESH KRISHNAN
Director
7,304 $548K
May 15, 2026 NICOLE LABROSSE
Former Officer
14,700 $987K
May 11, 2026 Helen Torley
President, CEO, Director
101,923 $6.5M
May 1, 2026 BERNADETTE CONNAUGHTON
Director
4,875 $310K
Mar 10, 2026 CORTNEY A CAUDILL
Officer
8,857 $599K
Mar 9, 2026 CORTNEY A CAUDILL
Officer
20,000 $1.4M
Feb 3, 2026 Helen Torley
President, CEO, Director
150,000 $11.2M
Jan 5, 2026 BERNADETTE CONNAUGHTON
Director
2,000 $141K
Show the other 4 notices

From the Form 144 XML filed with the SEC, since Jan 5, 2026. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.

Sources

Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.

Also

Insider trades: the Form 4s for the sales these plans led to.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/HALO/export.csv") into a cell.

Next:Owners
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.